Gilead (GILD) is to acquire Tubulis for USD 3.15bln in cash, and up to USD 1.85bln contingent, Bloomberg reports

Gilead's acquisition of Tubulis for approximately $3.15 billion in cash, with additional contingent payments, indicates a strategic expansion into biotechnology that could enhance its pipeline.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

US President Trump says a whole civilization will die tonight, never to be brought back again; does not want that to happen, but it probably will

Commerzbank (CBK GY) reaffirms upside potential of its existing business strategy and currently sees no basis for a mutually agreed value-accretive transaction after interactions with UniCredit (UCG IM)

Gilead (GILD) is to acquire Tubulis for USD 3.15bln in cash, and up to USD 1.85bln contingent, Bloomberg reports

US VP Vance says he wants to help Hungarian PM Orban as much as he can as he heads to the election

Strikes on Kharg Island were carried out solely by the US, not Israel, according to Fox News

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This move is significant as it not only reflects confidence in Tubulis' potential but may also impact Gilead's stock valuation and sector sentiment, particularly within biotech. Look for near-term reactions in Gilead's shares and broader implications for similar firms in the sector.

Related headlines

The whole workspace, free to try.

Try it free